GlassScriptPhysician profile
Satish Odhav
NPI 1679610745
$527,278.86
in general payments reported to CMS, 2019-2025
33 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240K · 2020: $59K · 2021: $42K · 2022: $39K · 2023: $68K · 2024: $23K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Travel and Lodging: $18K · Consulting Fee: $12K · Food and Beverage: $9,565 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,527.50 |
| Travel and Lodging | $17,850.44 |
| Consulting Fee | $11,800.00 |
| Food and Beverage | $9,565.04 |
| Education | $183.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $230,488.21 | 2019-2024 | Taltz |
| Abbvie INC. | $113,575.16 | 2019-2025 | |
| Celgene Corporation | $52,725.75 | 2019 | |
| Ucb, INC. | $36,184.10 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $31,066.53 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $25,879.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $14,875.88 | 2019-2020 | |
| Janssen Biotech, INC. | $7,826.95 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Gilead Sciences, INC. | $5,404.97 | 2020 | |
| Pfizer INC. | $3,324.05 | 2019-2025 | |
| Genzyme Corporation | $1,358.11 | 2020-2025 | |
| Ucb Sa | $1,042.13 | 2024 | |
| Glaxosmithkline, LLC. | $705.20 | 2020-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $512.50 | 2021-2025 | Saphnelo, Flumist Quadrivalent, Evusheld |
| Aurinia Pharma U.S., INC. | $326.24 | 2021-2024 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $316.57 | 2020-2025 | Acthar |
| Radius Health, INC. | $276.75 | 2019-2024 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $266.07 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.71 | 2023-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $210.49 | 2019-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $162.42 | 2019-2023 | Tremfya |
| Mallinckrodt Enterprises LLC | $97.88 | 2019 | |
| Sobi, INC | $89.96 | 2019-2022 | |
| Genentech USA, INC. | $89.61 | 2019-2025 | Actemra, Gazyva |
| Ultragenyx Pharmaceutical INC. | $81.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.15 | 2025 | Winrevair |
| Sandoz INC. | $21.50 | 2023 | Hyrimoz |
| Pacira Pharmaceuticals Incorporated | $19.66 | 2023 | Iovera, Zilretta |
| Organon LLC | $15.08 | 2021 | |
| Genentech, INC. | $15.00 | 2023 | Actemra, Gazyva |
| Kyowa Kirin, INC. | $14.05 | 2023 | Crysvita |
| Regeneron Pharmaceuticals, INC. | $12.92 | 2019 | |
| Fresenius Kabi USA, LLC | $12.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Odhav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.